DGAP-Adhoc: Powerland AG: Preliminary Results - Publication

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Apr 29, 2015 at 1:45 AM

DGAP-Adhoc: Powerland AG: Preliminary Results - Publication of audited consolidated financial statements rescheduled till the end of May 2015

Powerland AG / Key word(s): Preliminary Results 29.04.2015 07:38 Dissemination of an Ad hoc announcement according to Â§ 15 WpHG, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Preliminary Results - Publication of audited consolidated financial statements rescheduled till the end of May 2015 Frankfurt/Main, April 29, 2015 - Powerland AG (ISIN DE000PLD5558 / Prime Standard), the leading Chinese company of premium handbags, leather goods and accessories, hereby announces the following preliminary results: In the financial year of 2014, group revenue reached EUR 175.1 million, thus growing by 4.8% against the previous year 2013. The revenue of the luxury segment reached EUR 120.7 million and thus grew by 15.8% against the previous year 2013. Group consolidated gross profit for 2014 stood at EUR 60.6 million and thus declined somewhat by 0.4% against the previous year 2013. The Group gross margin was 34.6%. The gross profit of the luxury segment reached EUR 50.9 million and thus grew by 7.9% against the previous year 2013. Sales and distribution expenses for the business year 2014 stood at EUR 29.3 million and thus declined by 13.2% against the previous year 2013 while administrative expenses reached EUR 21.0 million and thus grew by 40.2% against the previous year 2013. As a result, group EBIT for 2014 was EUR 10.7 million and declined by 13.3% against the previous year 2013 to an EBIT margin of 6.1%. Group net profit for 2014 stood at EUR 3.8 million and declined by 45.0% against the previous year 2013. The net profit margin for 2014 was therefore 2.1%. Earnings per share decreased to EUR 0.25 in contrast to EUR 0.46 in the year 2013. As of 31 December 2014, cash and cash equivalents were EUR 8.7 million. On a year-on-year basis, group inventory decreased by 41.6% to EUR 17.7 million while trade and other receivables increased by 11.0% to EUR 107.7 million. Equity ratio increased to 78.5% in contrast to 68.9% as of 31 December 2013. The preliminary figures are subject to confirmation by the auditors and approval of the Supervisory Board. In general, the audit of the financial statements is almost completed. However, due to the late Chinese New Year and the even more sophisticated investigations of the 2014 accounts, the completion of the auditing practice takes longer than expected and Powerland hereby reschedules the publication of the audited annual consolidated financial statements together with the audited stand-alone financial statements until the end of May 2015. The date of the AGM will be delayed consequently. For further information, please contact: Powerland AG c/o GFD - Gesellschaft fÃ¼r Finanzkommunikation mbH Fellnerstrasse 7-9 60322 Frankfurt am Main Germany Phone: +49 (0) 69 66 554 - 459 Fax: +49 (0) 69 66 554 - 276 E-mail: ir@powerland.ag Home: http://www.powerland.ag 29.04.2015 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Powerland AG c/o GFD mbH, Fellnerstr. 7-9 60322 Frankfurt am Main Germany Phone: +49 69 - 66554-459 Fax: +49 69 - 66554-276 E-mail: ir@powerland.ag Internet: www.powerland.ag ISIN: DE000PLD5558 WKN: PLD555 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Novo's Semaglutide Shows Promise in MASH Study

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Webull Faces Class Action Suit: Key Deadlines Loom

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Fibocom LTE Modules Test Drive Satellite Connectivity

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

D-Wave's Legal Trouble: Securities Fraud Suit Looms

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Cultural Tech Fusion: The Asia-Pacific Way Forward

A High-Tech Twist on Traditional Culture You ever walk into a room and see a robot perform kung fu? I'll admit, it caught me off guard at first. But that's exactly what happened at the "Enduring Heritage, Harmonious Asia-Pacific" special exhibition in Shenzhen. With all the usual high-ranking execs and cultural bigwigs there, nobody expected a showcase where Wing Chun...

CureGene's Evategrel Aims for Breakthrough in Stroke Care

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

LG's ASIL D Certification: A Game Changer in Autos

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...

GlycoNex Eyes Japanese Market with Denosumab Biosimilar

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...